+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Environmental Scan on Pharmaceuticals Requiring Companion Diagnostics

Environmental Scan on Pharmaceuticals Requiring Companion Diagnostics

International Journal of Technology Assessment in Health Care 32(5): 327-336

Companion diagnostic tests (CDx) are used to measure an individual's protein or gene expression (biomarkers) to inform choice of therapy. The increasing number of drugs requiring CDx poses challenges for regulatory and reimbursement policies. To better understand this issue, an environmental scan was conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH). The environmental scan was based on a focused literature search and feedback solicited from targeted stakeholders. The global market for CDx is expected to grow considerably until the end of this decade, with compound annual growth rate around 20 percent. Several factors may impact the adoption of CDx, including the potential cost-savings associated with reduced treatment failures and adverse reactions. Anticipating an expansion in drugs with CDx, some countries have updated their regulatory frameworks, including the United States where the FDA released new guidance in 2014. With respect to reimbursement, both the United Kingdom and Australia updated their evaluation frameworks to inform reimbursement decisions; however, several countries, including Canada, have not published policies for co-dependent technology. The market size for CDx is expected to considerably expand in the future. The drive in uptake may be influenced by many factors including an increased knowledge of biomarkers and molecular drivers of disease and the potential cost-savings associated with fewer treatment failures and adverse reactions. Assessing whether such benefits materialize is important. Health technology assessment will play an important role in informing policies regarding the clinical use and funding of pharmaceuticals with CDx.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057777010

Download citation: RISBibTeXText

PMID: 27955717

DOI: 10.1017/s0266462316000532

Related references

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine 6(1):, 2016

Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Review of Molecular Diagnostics 15(7): 869-880, 2016

The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics. Biomarkers in Medicine 10(12): 1261-1268, 2016

The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics. Expert Review of Molecular Diagnostics 15(6): 815-827, 2015

Diagnostics and personalized medicine: observations from the World Companion Diagnostics Summit. Pharmacogenomics 12(4): 465-470, 2011

Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. Expert Opinion on Medical Diagnostics 5(2): 91-94, 2011

Progress and potential of RAS mutation detection for diagnostics and companion diagnostics. Expert Review of Molecular Diagnostics 16(10): 1067-1072, 2016

Personalized medicine, pharmacogenomics, and companion diagnostics. Current and future applications of molecular diagnostics will influence these emerging fields. Mlo: Medical Laboratory Observer 47(2): 22-23, 2015

Are companion diagnostics useful?. Clinical Chemistry 59(1): 198-201, 2013

Companion diagnostics. Clinical Advances in Hematology and Oncology 8(7): 478-479, 2010

Distributed robust adaptive control of high order nonlinear multi agent systems. Isa Transactions 74: 14-27, 2018

"Companion diagnostics": has their time come and gone?. Clinical Cancer Research 20(17): 4422-4424, 2014

Development of Companion Diagnostics. Seminars in Nuclear Medicine 46(1): 47-56, 2016

Illicit drugs and pharmaceuticals in the environment--forensic applications of environmental data, Part 2: Pharmaceuticals as chemical markers of faecal water contamination. Environmental Pollution 157(6): 1778-1786, 2009